{"hands_on_practices": [{"introduction": "Many proto-oncogenes, such as Ras, function as tightly regulated molecular switches. By modeling the kinetics of the Ras GTPase cycle, we can gain a quantitative understanding of how this switch maintains a low level of activity in normal cells. This exercise challenges you to derive the steady-state activity of Ras and then calculate how an oncogenic mutation, like the classic G12V substitution, disrupts this balance, leading to persistent activation and uncontrolled signaling [@problem_id:2843645].", "problem": "Ras proteins are small guanosine triphosphatases (GTPases) that cycle between guanosine diphosphate (GDP)-bound (inactive) and guanosine triphosphate (GTP)-bound (active) states. In cells, Guanine nucleotide Exchange Factors (GEF) catalyze exchange of GDP for GTP, while GTPase-Activating Proteins (GAP) stimulate GTP hydrolysis. Consider a well-mixed system in which the total Ras concentration is constant, and assume that nucleotide concentrations are buffered so that GEF-mediated exchange and GAP-stimulated hydrolysis can be treated as effective pseudo-first-order processes with rate constants $k_{on}$ for the GDP $\\to$ GTP transition and $k_{off}$ for the GTP $\\to$ GDP transition, respectively.\n\n- Let $x(t)$ denote the fraction of total Ras that is in the GTP-bound form at time $t$. Starting from mass-action principles and conservation of total Ras, derive an expression for the steady-state fraction $x^{\\ast}$ of Ras in the GTP-bound state for wild-type Ras.\n- The oncogenic mutation G12V (glycine to valine at position $12$) impairs catalysis of GTP hydrolysis and reduces the effective hydrolysis rate to a fraction $\\beta$ of its wild-type value, with $0  \\beta  1$. Denote the mutant steady-state fraction by $x^{\\ast}_{\\mathrm{G12V}}$.\n\nReport the fold change $F$ in the active-state occupancy due to the mutation, defined as $F = x^{\\ast}_{\\mathrm{G12V}}/x^{\\ast}$. Your final answer must be a single closed-form analytic expression in terms of $k_{on}$, $k_{off}$, and $\\beta$. Do not include units. If you introduce any intermediate quantities, eliminate them in the final expression for $F$.", "solution": "Let $[R_{GTP}]$ be the concentration of Ras in the active, GTP-bound state and $[R_{GDP}]$ be the concentration of Ras in the inactive, GDP-bound state. The total concentration of Ras, $[R]_{total}$, is constant, such that $[R]_{total} = [R_{GTP}] + [R_{GDP}]$.\n\nThe fraction of Ras in the active state is defined as $x(t) = \\frac{[R_{GTP}](t)}{[R]_{total}}$. Consequently, the fraction of Ras in the inactive state is $1 - x(t) = \\frac{[R_{GDP}](t)}{[R]_{total}}$.\n\nThe kinetic scheme is a reversible pseudo-first-order reaction:\n$$ R_{GDP} \\underset{k_{off}}{\\stackrel{k_{on}}{\\rightleftharpoons}} R_{GTP} $$\n\nBased on mass-action principles, the rate of change of the concentration of active Ras, $[R_{GTP}]$, is given by the difference between its rate of formation and its rate of consumption:\n$$ \\frac{d[R_{GTP}]}{dt} = k_{on}[R_{GDP}] - k_{off}[R_{GTP}] $$\n\nTo express this in terms of the fraction $x(t)$, we divide the entire equation by the constant total concentration $[R]_{total}$:\n$$ \\frac{1}{[R]_{total}} \\frac{d[R_{GTP}]}{dt} = k_{on} \\frac{[R_{GDP}]}{[R]_{total}} - k_{off} \\frac{[R_{GTP}]}{[R]_{total}} $$\n\nRecognizing that $\\frac{d}{dt}\\left(\\frac{[R_{GTP}]}{[R]_{total}}\\right) = \\frac{dx}{dt}$, we obtain the differential equation governing the fraction of active Ras:\n$$ \\frac{dx}{dt} = k_{on}(1 - x) - k_{off}x $$\n\nAt steady-state, the system does not change in time, so $\\frac{dx}{dt} = 0$. Let $x^{\\ast}$ be the steady-state fraction of active wild-type Ras. The steady-state condition is:\n$$ 0 = k_{on}(1 - x^{\\ast}) - k_{off}x^{\\ast} $$\n\nWe solve this algebraic equation for $x^{\\ast}$:\n$$ k_{on} - k_{on}x^{\\ast} - k_{off}x^{\\ast} = 0 $$\n$$ k_{on} = x^{\\ast}(k_{on} + k_{off}) $$\n$$ x^{\\ast} = \\frac{k_{on}}{k_{on} + k_{off}} $$\n\nNext, we consider the mutant protein. The mutation reduces the hydrolysis rate constant from $k_{off}$ to $\\beta k_{off}$. The activation rate constant $k_{on}$ remains unchanged. The steady-state equation for the mutant, with its active fraction denoted by $x^{\\ast}_{\\mathrm{G12V}}$, is found by replacing $k_{off}$ with $\\beta k_{off}$ in the steady-state equation:\n$$ 0 = k_{on}(1 - x^{\\ast}_{\\mathrm{G12V}}) - (\\beta k_{off})x^{\\ast}_{\\mathrm{G12V}} $$\n\nSolving this for $x^{\\ast}_{\\mathrm{G12V}}$:\n$$ k_{on} - k_{on}x^{\\ast}_{\\mathrm{G12V}} - \\beta k_{off}x^{\\ast}_{\\mathrm{G12V}} = 0 $$\n$$ k_{on} = x^{\\ast}_{\\mathrm{G12V}}(k_{on} + \\beta k_{off}) $$\n$$ x^{\\ast}_{\\mathrm{G12V}} = \\frac{k_{on}}{k_{on} + \\beta k_{off}} $$\n\nThe problem asks for the fold change $F$, defined as the ratio of the mutant steady-state fraction to the wild-type steady-state fraction, $F = \\frac{x^{\\ast}_{\\mathrm{G12V}}}{x^{\\ast}}$.\nSubstituting the derived expressions for $x^{\\ast}_{\\mathrm{G12V}}$ and $x^{\\ast}$:\n$$ F = \\frac{\\left( \\frac{k_{on}}{k_{on} + \\beta k_{off}} \\right)}{\\left( \\frac{k_{on}}{k_{on} + k_{off}} \\right)} $$\n\nWe simplify the compound fraction:\n$$ F = \\frac{k_{on}}{k_{on} + \\beta k_{off}} \\cdot \\frac{k_{on} + k_{off}}{k_{on}} $$\n\nThe term $k_{on}$ in the numerator and denominator cancels, yielding the final expression for the fold change:\n$$ F = \\frac{k_{on} + k_{off}}{k_{on} + \\beta k_{off}} $$\nThis expression is in terms of the required parameters $k_{on}$, $k_{off}$, and $\\beta$. Since $0  \\beta  1$, the denominator $k_{on} + \\beta k_{off}$ is smaller than the numerator $k_{on} + k_{off}$, which correctly implies that $F > 1$, consistent with the known oncogenic effect of an increased population of active Ras.", "answer": "$$ \\boxed{\\frac{k_{on} + k_{off}}{k_{on} + \\beta k_{off}}} $$", "id": "2843645"}, {"introduction": "In contrast to the activating 'one-hit' nature of oncogenes, the inactivation of tumor-suppressor genes typically requires 'two hits,' a principle elegantly formulated in Knudson's hypothesis. This model explains the dramatic difference in cancer incidence between sporadic cases and individuals with an inherited germline mutation. This practice delves into the mathematical underpinnings of this theory, using probability to model the stochastic accumulation of mutational hits and derive the characteristic age-incidence curves for both scenarios [@problem_id:2843565].", "problem": "A tumor-suppressor gene typically requires biallelic inactivation to contribute causally to carcinogenesis. In the classic Knudson two-hit framework, assume the following foundational principles:\n- Somatic loss-of-function “hits” to an allele occur as rare, independent events, well-modeled by a homogeneous Poisson process over age.\n- Consequently, the waiting time to each hit is exponentially distributed and is memoryless.\n- Cancer onset is triggered when both hits have occurred in the same stem-cell lineage, and the time from the second hit to clinical detection is negligible relative to the age scale considered.\n\nConsider an organ in which the age-specific somatic inactivation process for a single tumor-suppressor gene can be aggregated at the individual level as follows. In the sporadic case (no inherited mutation), the waiting time to the first allele-inactivating event after birth is an exponential random variable $X_{1} \\sim \\mathrm{Exp}(\\lambda_{1})$, where $\\lambda_{1} \\gt 0$ is the effective per-individual rate parameter that aggregates across all susceptible lineages. Conditional on the first hit, the waiting time to the second allele-inactivating event is $X_{2} \\sim \\mathrm{Exp}(\\lambda_{2})$, with $\\lambda_{2} \\gt 0$, independent of $X_{1}$. The cancer onset age is $T = X_{1} + X_{2}$. In the germline heterozygote case (one inherited inactive allele present at birth), only a single somatic hit is needed, so the cancer onset age is $T_{\\mathrm{g}} = X_{2}$ with the same $\\lambda_{2}$.\n\nAssume that disease is rare, so population depletion due to incident cases is negligible. Define the age-specific incidence density for onset as the probability density function of onset age, denoted $i_{\\mathrm{s}}(t)$ for the sporadic case and $i_{\\mathrm{g}}(t)$ for the germline heterozygote case, where $t \\ge 0$ is age.\n\nStarting only from the above principles and definitions (Poisson process for hits, exponential waiting times, and independence), derive $i_{\\mathrm{s}}(t)$ and $i_{\\mathrm{g}}(t)$ in closed form. Then obtain their small-$t$ expansions up to and including the first nontrivial term. Use these to formally quantify how germline heterozygosity alters the age-incidence curve at early ages by computing the leading-order small-$t$ expression for the ratio\n$$\nR_{\\mathrm{LO}}(t) \\equiv \\frac{i_{\\mathrm{s}}(t)}{i_{\\mathrm{g}}(t)} \\quad \\text{as } t \\to 0^{+}.\n$$\n\nProvide, as your final answer, the single closed-form analytic expression for $R_{\\mathrm{LO}}(t)$. No numerical evaluation is required. If any limiting case is needed (for example, $\\lambda_{1} = \\lambda_{2}$), justify it by an appropriate limiting argument, but the final answer must be a single explicit formula for $R_{\\mathrm{LO}}(t)$ that holds for small $t$ with $\\lambda_{1} \\gt 0$ and $\\lambda_{2} \\gt 0$ fixed. Express time $t$ in years if you refer to units in your reasoning; the final ratio is dimensionless and should be reported without units. Do not round; an exact symbolic expression is required.", "solution": "The task is to derive the age-specific incidence densities for sporadic and germline cases, denoted $i_{\\mathrm{s}}(t)$ and $i_{\\mathrm{g}}(t)$ respectively, and then to compute the leading-order small-age behavior of their ratio, $R_{\\mathrm{LO}}(t)$.\n\nFirst, consider the germline heterozygote case. An individual is born with one inactivated allele. Cancer onset requires a single somatic \"hit,\" the waiting time for which is given by the exponential random variable $T_{\\mathrm{g}} = X_{2} \\sim \\mathrm{Exp}(\\lambda_{2})$. The incidence density $i_{\\mathrm{g}}(t)$ is the probability density function (PDF) of $T_{\\mathrm{g}}$. For an exponential distribution with rate parameter $\\lambda_{2}$, the PDF is:\n$$\ni_{\\mathrm{g}}(t) = \\lambda_{2} \\exp(-\\lambda_{2} t) \\quad \\text{for } t \\ge 0\n$$\n\nNext, consider the sporadic case. An individual is born with two functional alleles. Cancer onset requires two independent somatic \"hits.\" The waiting time for the first hit is $X_{1} \\sim \\mathrm{Exp}(\\lambda_{1})$, and the subsequent waiting time for the second hit is $X_{2} \\sim \\mathrm{Exp}(\\lambda_{2})$. The total time to cancer onset is the sum $T = X_{1} + X_{2}$. Since $X_{1}$ and $X_{2}$ are independent random variables, the PDF of their sum, $i_{\\mathrm{s}}(t)$, is the convolution of their individual PDFs:\n$$\ni_{\\mathrm{s}}(t) = (f_{X_1} * f_{X_2})(t) = \\int_{0}^{t} f_{X_1}(\\tau) f_{X_2}(t-\\tau) d\\tau\n$$\nThe PDFs for $X_{1}$ and $X_{2}$ are $f_{X_1}(\\tau) = \\lambda_{1} \\exp(-\\lambda_{1} \\tau)$ and $f_{X_2}(t-\\tau) = \\lambda_{2} \\exp(-\\lambda_{2} (t-\\tau))$. Substituting these into the convolution integral gives:\n$$\ni_{\\mathrm{s}}(t) = \\int_{0}^{t} \\lambda_{1} \\exp(-\\lambda_{1} \\tau) \\lambda_{2} \\exp(-\\lambda_{2} (t-\\tau)) d\\tau = \\lambda_{1} \\lambda_{2} \\exp(-\\lambda_{2} t) \\int_{0}^{t} \\exp(-(\\lambda_{1}-\\lambda_{2})\\tau) d\\tau\n$$\nWe evaluate the integral, first assuming $\\lambda_{1} \\neq \\lambda_{2}$:\n$$\n\\int_{0}^{t} \\exp(-(\\lambda_{1}-\\lambda_{2})\\tau) d\\tau = \\left[ \\frac{\\exp(-(\\lambda_{1}-\\lambda_{2})\\tau)}{-(\\lambda_{1}-\\lambda_{2})} \\right]_{0}^{t} = \\frac{1 - \\exp(-(\\lambda_{1}-\\lambda_{2})t)}{\\lambda_{1}-\\lambda_{2}}\n$$\nSubstituting this back, we obtain the PDF for the sporadic case, which is a hypoexponential distribution:\n$$\ni_{\\mathrm{s}}(t) = \\lambda_{1} \\lambda_{2} \\exp(-\\lambda_{2} t) \\frac{1 - \\exp(-(\\lambda_{1}-\\lambda_{2})t)}{\\lambda_{1}-\\lambda_{2}} = \\frac{\\lambda_{1} \\lambda_{2}}{\\lambda_{1}-\\lambda_{2}} (\\exp(-\\lambda_{2} t) - \\exp(-\\lambda_{1} t))\n$$\nThis formula is valid for $\\lambda_{1} \\neq \\lambda_{2}$. The problem requires a single expression, so we must verify its behavior for the case $\\lambda_{1} = \\lambda_{2}$. When $\\lambda_{1} = \\lambda_{2} = \\lambda$, the sum of two independent and identically distributed exponential random variables follows a Gamma distribution, specifically $T \\sim \\mathrm{Gamma}(2, \\lambda)$, with PDF $i_{\\mathrm{s}}(t) = \\lambda^{2} t \\exp(-\\lambda t)$. We demonstrate that our general formula correctly reduces to this in the limit. Let $\\lambda_{1} \\to \\lambda_{2}$. Using L'Hôpital's rule on the expression with respect to $\\lambda_{1}$:\n$$\n\\lim_{\\lambda_{1} \\to \\lambda_{2}} i_{\\mathrm{s}}(t) = \\lambda_{2} \\lim_{\\lambda_{1} \\to \\lambda_{2}} \\frac{\\lambda_{1}(\\exp(-\\lambda_{2} t) - \\exp(-\\lambda_{1} t))}{\\lambda_{1}-\\lambda_{2}} = \\lambda_{2} \\lim_{\\lambda_{1} \\to \\lambda_{2}} \\frac{\\frac{d}{d\\lambda_1} [\\lambda_{1}(\\exp(-\\lambda_{2} t) - \\exp(-\\lambda_{1} t))]}{\\frac{d}{d\\lambda_1} [\\lambda_{1}-\\lambda_{2}]}\n$$\nThe derivative of the numerator is $1 \\cdot (\\exp(-\\lambda_{2} t) - \\exp(-\\lambda_{1} t)) + \\lambda_{1}(t \\exp(-\\lambda_{1} t))$. The derivative of the denominator is $1$. In the limit $\\lambda_{1} \\to \\lambda_{2}$:\n$$\n\\lim_{\\lambda_{1} \\to \\lambda_{2}} i_{\\mathrm{s}}(t) = \\lambda_{2} [(\\exp(-\\lambda_{2} t) - \\exp(-\\lambda_{2} t)) + \\lambda_{2} t \\exp(-\\lambda_{2} t)] = \\lambda_{2}^{2} t \\exp(-\\lambda_{2} t)\n$$\nThis confirms the result for the $\\mathrm{Gamma}(2, \\lambda_{2})$ distribution. Therefore, the derived formula for $i_{\\mathrm{s}}(t)$, interpreted via its limit, is general.\n\nNow, we compute the ratio $R(t) = i_{\\mathrm{s}}(t) / i_{\\mathrm{g}}(t)$. For the general case $\\lambda_{1} \\neq \\lambda_{2}$:\n$$\nR(t) = \\frac{\\frac{\\lambda_{1} \\lambda_{2}}{\\lambda_{1}-\\lambda_{2}} (\\exp(-\\lambda_{2} t) - \\exp(-\\lambda_{1} t))}{\\lambda_{2} \\exp(-\\lambda_{2} t)} = \\frac{\\lambda_{1}}{\\lambda_{1}-\\lambda_{2}} \\frac{\\exp(-\\lambda_{2} t) - \\exp(-\\lambda_{1} t)}{\\exp(-\\lambda_{2} t)}\n$$\n$$\nR(t) = \\frac{\\lambda_{1}}{\\lambda_{1}-\\lambda_{2}} (1 - \\exp(-(\\lambda_{1}-\\lambda_{2})t))\n$$\nWe are asked for the leading-order small-$t$ expression, $R_{\\mathrm{LO}}(t)$, as $t \\to 0^{+}$. We perform a Maclaurin series expansion of $R(t)$ with respect to $t$. We use the expansion $\\exp(-x) = 1 - x + O(x^{2})$ for small $x$. Let $x = (\\lambda_{1}-\\lambda_{2})t$. As $t \\to 0^{+}$, $x \\to 0$.\n$$\n1 - \\exp(-(\\lambda_{1}-\\lambda_{2})t) = 1 - \\left(1 - (\\lambda_{1}-\\lambda_{2})t + O(t^{2})\\right) = (\\lambda_{1}-\\lambda_{2})t + O(t^{2})\n$$\nSubstituting this back into the expression for $R(t)$:\n$$\nR(t) \\approx \\frac{\\lambda_{1}}{\\lambda_{1}-\\lambda_{2}} [(\\lambda_{1}-\\lambda_{2})t] = \\lambda_{1} t\n$$\nThus, the leading-order small-$t$ expression for the ratio is:\n$$\nR_{\\mathrm{LO}}(t) = \\lambda_{1} t\n$$\nThis result is also consistent for the case $\\lambda_{1} = \\lambda_{2} = \\lambda$. In this instance, $i_{\\mathrm{s}}(t) = \\lambda^{2} t \\exp(-\\lambda t)$ and $i_{\\mathrm{g}}(t) = \\lambda \\exp(-\\lambda t)$. The ratio is exactly:\n$$\nR(t) = \\frac{\\lambda^{2} t \\exp(-\\lambda t)}{\\lambda \\exp(-\\lambda t)} = \\lambda t\n$$\nThis matches our general result $R_{\\mathrm{LO}}(t) = \\lambda_{1} t$ upon setting $\\lambda_{1} = \\lambda$.\n\nThe expression $R_{\\mathrm{LO}}(t) = \\lambda_{1} t$ reveals the fundamental difference in incidence patterns at early ages predicted by the model. The incidence of sporadic cancer rises linearly with age $t$, with a slope given by the rate of the first hit, $\\lambda_1$. In contrast, the incidence of germline cancer is approximately constant at early ages, $i_{\\mathrm{g}}(t) \\approx \\lambda_{2}$. The ratio is therefore linear in age, reflecting the requirement of an additional rare event (the first hit) in the sporadic pathway, the probability of which is proportional to time for small times.\n\nThe final answer is the derived closed-form analytic expression for $R_{\\mathrm{LO}}(t)$.", "answer": "$$\n\\boxed{\\lambda_{1} t}\n$$", "id": "2843565"}, {"introduction": "While the two-hit hypothesis provides a powerful framework for recessive tumor suppressors, many important suppressors, such as p53, function as protein complexes. In these cases, a mutation in a single allele can have a 'dominant-negative' effect, where the mutant protein interferes with the function of the normal protein. This exercise uses fundamental principles of probability to quantify how severely a dominant-negative variant can compromise the total functional pool of a dimeric tumor suppressor, explaining why heterozygosity can be almost as detrimental as complete loss of the gene [@problem_id:2843575].", "problem": "A tumor-suppressor transcription factor requires dimerization to bind deoxyribonucleic acid (DNA) and activate target genes that enforce cell-cycle checkpoints. In a diploid cell that is heterozygous for this gene, one allele is wild-type and the other encodes a dominant-negative variant that correctly dimerizes but cannot activate transcription. Assume the following foundational principles and conditions grounded in the Central Dogma of molecular biology and basic probability:\n\n- Both alleles are transcribed into messenger ribonucleic acid (mRNA) and translated into protein, yielding two monomer species: wild-type and dominant-negative.\n- The steady-state abundance of each monomer species is proportional to its protein production rate because both species share the same first-order degradation rate constant.\n- Dimerization is fast relative to synthesis and degradation and occurs by random association from a well-mixed monomer pool, with no assembly bias.\n- Only dimers composed of $2$ wild-type subunits are fully functional; any dimer containing at least $1$ dominant-negative subunit is nonfunctional (dominant-negative effect).\n\nLet the production rate of the wild-type monomer be $k_w$ and the production rate of the dominant-negative monomer be $k_m$. Define the production-rate ratio $r = \\frac{k_m}{k_w}$. Using only these assumptions and basic probability, derive the exact closed-form expression for the probability that a randomly assembled dimer is fully functional, expressed solely in terms of $r$.\n\nAnswer form: Provide a single closed-form analytic expression. Do not include units.", "solution": "The problem requires the derivation of the probability that a randomly assembled dimer is functional. A functional dimer is defined as being composed of two wild-type subunits. Let the wild-type monomer species be denoted by $W$ and the dominant-negative monomer species by $M$.\n\nFirst, we establish the relationship between the steady-state abundance of each monomer species and its production rate. The problem states that for each species, the steady-state concentration is achieved when the rate of production equals the rate of degradation. Both species share the same first-order degradation rate constant, which we will denote as $\\lambda$.\n\nLet $[W]$ and $[M]$ represent the steady-state concentrations (or abundances) of the wild-type and dominant-negative monomers, respectively. The production rates are given as $k_w$ for the wild-type monomer and $k_m$ for the dominant-negative monomer. The degradation rates are $\\lambda[W]$ and $\\lambda[M]$, respectively.\n\nAt steady state, we have:\nFor the wild-type monomer:\n$$k_w = \\lambda [W]$$\nFor the dominant-negative monomer:\n$$k_m = \\lambda [M]$$\n\nFrom these equations, we can express the steady-state concentrations in terms of the production rates and the degradation rate constant:\n$$[W] = \\frac{k_w}{\\lambda}$$\n$$[M] = \\frac{k_m}{\\lambda}$$\n\nNext, we consider the process of dimerization. Dimerization is stated to occur by random association from a well-mixed pool of monomers. This implies that the probability of selecting a monomer of a specific type for dimerization is equal to its mole fraction in the total monomer pool.\n\nLet $P(W)$ be the probability of selecting a wild-type monomer and $P(M)$ be the probability of selecting a dominant-negative monomer. These probabilities are given by:\n$$P(W) = \\frac{[W]}{[W] + [M]}$$\n$$P(M) = \\frac{[M]}{[W] + [M]}$$\n\nWe substitute the expressions for $[W]$ and $[M]$ into the equation for $P(W)$:\n$$P(W) = \\frac{\\frac{k_w}{\\lambda}}{\\frac{k_w}{\\lambda} + \\frac{k_m}{\\lambda}}$$\nThe degradation rate constant $\\lambda$ cancels out from the numerator and the denominator, which is expected as the relative abundance depends only on the ratio of production rates when degradation rates are equal.\n$$P(W) = \\frac{k_w}{k_w + k_m}$$\n\nThe problem defines the production-rate ratio as $r = \\frac{k_m}{k_w}$. To express $P(W)$ in terms of $r$, we divide the numerator and the denominator of the fraction by $k_w$:\n$$P(W) = \\frac{\\frac{k_w}{k_w}}{\\frac{k_w}{k_w} + \\frac{k_m}{k_w}} = \\frac{1}{1 + r}$$\n\nAccording to the problem statement, a dimer is fully functional only if it is composed of $2$ wild-type subunits. This corresponds to the formation of a $W_2$ dimer. Since dimerization involves the random association of two monomers, the formation of a $W_2$ dimer requires two independent events: the selection of a wild-type monomer, followed by the selection of another wild-type monomer.\n\nThe probability of forming a functional dimer, which we denote as $P(\\text{functional})$, is therefore the probability of forming a $W_2$ dimer, $P(W_2)$. This is a compound probability of two independent events:\n$$P(\\text{functional}) = P(W_2) = P(W) \\times P(W) = (P(W))^2$$\n\nFinally, we substitute our expression for $P(W)$ in terms of $r$ into this equation to obtain the final answer:\n$$P(\\text{functional}) = \\left(\\frac{1}{1 + r}\\right)^2$$\nThis expression gives the probability that a randomly assembled dimer is fully functional, expressed solely in terms of the production-rate ratio $r$.", "answer": "$$\n\\boxed{\\frac{1}{(1 + r)^{2}}}\n$$", "id": "2843575"}]}